HCW11-006 / HCW Biologics, WY Biotech - LARVOL DELTA

Enhancing immune cell expansion, checkpoint inhibitor synergy, and in vivo CAR-T and lymphocyte support using HCW11-006-a novel cytokine fusion molecule (SITC 2025) - "The molecule effectively supports the development of TSCM cells, enhances CAR-T cell functionality, and synergizes with immune checkpoint inhibitors. HCW11-006 represents a promising immunotherapeutic agent capable of inducing both immediate and durable anti-tumor immune responses.Ethics Approval HCW Biologics IACUC Committee Protocol number VG2025-009"

Checkpoint inhibition • Immune cell • Preclinical • Acute Myelogenous Leukemia • Bladder Cancer • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • CD8 • IL15 • IL21 • IL7

HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer (HCW Biologics Press Release) - "Company poster presentations will debut research data of three lead drug candidates constructed with Company’s novel TRBC platform technology."

Preclinical • Oncology